161 related articles for article (PubMed ID: 37878148)
1. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers SWM; Thurisch H; Vriens IJH; Meegdes M; Engelen SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Peters NAJB; Tol J; Heijns JB; van de Wouw AJ; Teeuwen NJA; Geurts SME; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jan; 203(2):339-349. PubMed ID: 37878148
[TBL] [Abstract][Full Text] [Related]
2. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
3. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Kim JY; Lee DW; Lee KH; Min A; Ryu HS; Lee HB; Moon HG; Kim TY; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA; Kim S
Breast Cancer Res Treat; 2019 Jul; 176(2):453-460. PubMed ID: 31028608
[TBL] [Abstract][Full Text] [Related]
5. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
6. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
7. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Widschwendter P; Friedl TW; Schwentner L; DeGregorio N; Jaeger B; Schramm A; Bekes I; Deniz M; Lato K; Weissenbacher T; Kost B; Andergassen U; Jueckstock J; Neugebauer J; Trapp E; Fasching PA; Beckmann MW; Schneeweiss A; Schrader I; Rack B; Janni W; Scholz C
Breast Cancer Res; 2015 Sep; 17(1):129. PubMed ID: 26385214
[TBL] [Abstract][Full Text] [Related]
8. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
9. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
[TBL] [Abstract][Full Text] [Related]
10. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
[TBL] [Abstract][Full Text] [Related]
11. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Martel S; Lambertini M; Agbor-Tarh D; Ponde NF; Gombos A; Paterson V; Hilbers F; Korde L; Manukyants A; Dueck A; Maurer C; Piccart M; Moreno-Aspitia A; Desmedt C; Di Cosimo S; de Azambuja E
J Natl Compr Canc Netw; 2021 Jan; 19(2):181-189. PubMed ID: 33401235
[TBL] [Abstract][Full Text] [Related]
12. Impact of body mass index on overall survival in patients with metastatic breast cancer.
Saleh K; Carton M; Dieras V; Heudel PE; Brain E; D'Hondt V; Mailliez A; Patsouris A; Mouret-Reynier MA; Goncalves A; Ferrero JM; Petit T; Emile G; Uwer L; Debled M; Dalenc F; Jouannaud C; Ladoire S; Leheurteur M; Cottu P; Veron L; Savignoni A; Courtinard C; Robain M; Delaloge S; Deluche E
Breast; 2021 Feb; 55():16-24. PubMed ID: 33307392
[TBL] [Abstract][Full Text] [Related]
13. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
Van Baelen K; Nguyen HL; Hamy-Petit AS; Richard F; Karsten MM; Nader Marta G; Vermeulen P; Toussaint A; Reyal F; Vincent-Salomon A; Dirix L; Dordevic AD; de Azambuja E; Larsimont D; Amato O; Maetens M; De Schepper M; Geukens T; Han SN; Baert T; Punie K; Wildiers H; Smeets A; Nevelsteen I; Floris G; Biganzoli E; Neven P; Desmedt C
Eur J Cancer; 2023 Sep; 191():112988. PubMed ID: 37573673
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Lammers SWM; Geurts SME; van Hellemond IEG; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; de Roos WK; Linn SC; Imholz ALT; Smidt ML; Vriens IJH; Tjan-Heijnen VCG
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37991939
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients.
Ko SM; Lee J; Bae SJ; Baik SJ; Ji J; Kim D; Ahn SG; Jeong J
Br J Cancer; 2021 Jul; 125(1):119-125. PubMed ID: 33875823
[TBL] [Abstract][Full Text] [Related]
16. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
[TBL] [Abstract][Full Text] [Related]
17. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Franzoi MA; Eiger D; Ameye L; Ponde N; Caparica R; De Angelis C; Brandão M; Desmedt C; Di Cosimo S; Kotecki N; Lambertini M; Awada A; Piccart M; Azambuja E
J Natl Cancer Inst; 2021 Apr; 113(4):462-470. PubMed ID: 32750143
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
20. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Ibragimova KIE; Geurts SME; Croes S; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel L; Tilli DJP; Vriens IJH; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2021 Jul; 188(2):571-581. PubMed ID: 33743103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
